Obviously we don't know whether they are planning to license...

Obviously we don't know whether they are planning to license PI-88 for individual cancers or a package - but if they are seeking to license individually as you point out they have completed Phase II Efficacy endpoint for Multiple Myeloma, which although is not a major cancer in the scheme of things - about 1% of all cancers, is still a major disease with about 13,000 people diagnosed in the UsA alone each year.

http://www.nci.nih.gov/cancer_information/doc_wyntk.aspx?viewid=5db34eef-d9c1-47dd-94e1-3c98099798ba